you attend the first study visit after joining the trial.

the study staff explains the purpose of the trial and obtains your written consent.

baseline measurements are taken, including disease activity scores and blood samples.

you receive the first subcutaneous injection of daxdilimab (300 mg) or a matching placebo, administered under the skin.

you continue taking your regular oral prednisone tablets, 20 mg once daily, as prescribed before the study.

you return to the study site for follow‑up visits that are scheduled approximately every four weeks, continuing until week 24.

at each visit you receive another subcutaneous injection of daxdilimab (300 mg) or placebo, according to the randomization assignment.

your oral prednisone dose of 20 mg daily is maintained throughout the treatment period unless a dose reduction is advised by the study physician based on predefined criteria.

the study team records disease activity scores, performs safety assessments, and collects blood samples to measure drug levels and antibodies.

during the follow‑up visits you undergo assessments that include the total improvement score (tis) and the cdasi activity score, which evaluate changes in skin and muscle involvement.

any side effects or adverse events are documented and evaluated at each visit.

blood tests are performed to monitor the concentration of daxdilimab and to check for the presence of antidrug antibodies.

you attend the last study visit at week 24, which marks the end of the treatment period.

the final disease activity scores are recorded, and blood samples are taken for the final pharmacokinetic and safety analysis.

the study team evaluates whether a clinically meaningful reduction in the prednisone dose (at least a 25 % decrease or a dose of 7.5 mg/day) has been achieved, if you were on a dose of 10 mg or more at baseline.

after the final assessments the investigational treatment is discontinued and you are provided with information about post‑study follow‑up, if any.